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ABSTRACT We have determined the mutational spectrum
of N-ethyl-N-nitrosourea (ENU) in exon 3 of the hypoxanthine
guanine) phosphoribosyltransferase gene (Hprt) in splenic T
cells following in vivo exposure of male B6C3F1 mice (5-7 weeks
old) to ENU. Hpir mutants were isolated by culturing splenic
T cells in microtiter dishes containing medium supplemented
with interleukin 2, concanavalin A, and 6-thiouanine. DNA
was extracted from 6-thoa ne-sistant colonies and ampli-
fied by the polymerase chain reaction (PCR) using primers
flanking Hprt exon 3. Identification of mutant sequences and
purification of mutant DNA from contaminating wild-type Hprt
DNA was accomplished by denaturing-adient gel electropho-
resis. Purified mutant DNA was then sequenced. Treatment of
mice with ENU at 40 mg/kg of body weight produced a Hprr
mutant frequency of 7.3 x 10-5 in splenic T cells, =35-fold
above background levels. Sixty-nine of the 521 HprF mutants
analyzed contained mutations in exon 3 (13%). Tranversions
and transitions at AFT base pais dominated the spectrum; 62 of
the 69 exon 3 mutations were at AKT base pairs (14 different
sites). Thirteen of 14 thymine bases undergoing mutation (61 of
62 mutations at AFT bases) were located on the nontranscribed
stand of exon 3. The majority of the remaining mutations (6 of
69) were transitions at a single G'C base -i. These results
suggest the importance of thymidine alkylation in ENU-induced
mutagenesis in vivo. The mouse HpW- T-cell cloning/sequenc-
ing assay described here may represent a useful system for
studying the molecular mechanism of chemically induced mu-
tation occurring in vivo in an endogenous gene.
Chemically induced mutation in vivo is the end result of a
complicated cascade of events including compound uptake
and distribution, metabolic activation/detoxification, com-
pound interaction with DNA, DNA repair, and cell replica-
tion. The complexity of this pathway suggests that in vivo
mutagenesis assays may be more relevant than in vitro
systems for modeling possible mutagenic consequences in
humans. In vivo mutation assays based on the cloning of
hypoxanthine (guanine) phosphoribosyltransferase (HPRT)-
negative T cells have been developed in the mouse (1-3), rat
(4), monkey (5), and human (6, 7). Recently, transgenic
mouse systems have also been described that contain bac-
terial transgenes as mutational targets (8, 9). These systems
provide excellent opportunities to quantitate and compare
the type and frequency of mutations occurring in vivo in
different sequence contexts.
The type of base-pair changes produced in DNA can offer
important insight regarding the specific DNA adducts and
mutagenic mechanisms involved in the mutagenic event. To
this end, our group has developed a method to sequence Hprt
mutations induced in vivo in splenic T cells of B6C3F1 mice,
the strain presently used in the National Toxicology Program
cancer bioassays. The approach utilizes denaturing-gradient
gel electrophoresis (DGGE) (10-12) to purify mutant se-
quences for analysis. DGGE is based on the fact that the
electrophoretic mobility of a DNA molecule in a polyacryl-
amide gel is considerably reduced as the molecule becomes
partially melted (denatured). Mismatched heteroduplexes
formed by annealing wild-type and mutant DNA sequences
are always less stable than the corresponding perfectly base-
paired homoduplexes and consequently melt at a lower
concentration of denaturant. Therefore, any mutant/wild-
type heteroduplex will always travel a shorter distance rel-
ative to wild-type homoduplexes in a gel containing a dient
ofdenaturant. It is predicted that heteroduplex formation and
DGGE analysis will resolve any base substitution, frame-
shift, or small deletions (<10 base pairs) in the low-
temperature melting domain of a DNA molecule (11). Also,
since the addition of G+C-rich primers can modify the
melting characteristics of the DNA molecule under study, all
regions can be analyzed (12).
Methods to analyze mutations in the exon 3 region of the
human HPRT gene byDGGE have been developed previously
(13). Since the sequence of exon 3 and flanking intron regions
of mouse Hprt have been determined (14), we sought to
develop similar DGGE methods to analyze mutations isolated
by the mouse HprtU T-cell cloning assay (1-3). We have used
these methods to determine the mutational spectrum of
N-ethyl-N-nitrosourea (ENU) in B6C3F1 mice.
ENU is a well-characterized ethylating agent that produces
a variety of DNA modifications, including the potent pro-
mutagenic adducts 06-ethylguanine and 04-ethylthymine
(15, 16). These lesions produce predominantly transition
mutations at G-C and A-T base pairs (17, 18). Recently, the
mutagenic potential of another ethyl adduct, 02-ethylthy-
mine, has been demonstrated in Escherichia coli and has
been shown to result mainly in transversions (19). We report
here that mutations induced by ENU in vivo are predomi-
nantly transversion and transition mutations at AFT base
pairs, and we contrast these results with ENU spectral data
obtained in other systems.
MATERIALS AND METHODS
Chemicals, Enzymes, and Medium Components. Materials
were obtained from the indicated sources: fetal bovine serum
(GIBCO); RPMI-1640, Hepes buffer, glutamine, MEM non-
essential amino acids, penicillin/streptomycin mixture, and
sodium pyruvate (Lineberger Cancer Research Center, Tis-
sue Culture Facility, University of North Carolina at Chapel
Hill); HL-1 medium (Ventrex Laboratories, Portland, ME);
ENU (in aqueous 23% acetic acid as stabilizer) (Sigma);
deoxynucleoside triphosphates (Pharmacia LKB), Seque-
nase, dideoxynucleoside triphosphates, and concanavalin A
(United States Biochemical); AmpliTaq DNA polymerase
(Perkin-Elmer/Cetus); Lympholyte M (Cedarlane Labora-
tories, Hornby, ON, Canada).
Abbreviations: ENU, N-ethyl-N-nitrosourea; HPRT, hypoxanthine
(guanine) phosphoribosyltransferase; DGGE, denaturing-gradient gel
electrophoresis; 6TG, 6-thioguanine; PE, plating efficiency.
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Mice and ENU Treatment. Male B6C3F1 mice (5-7 weeks
old) were obtained from Charles River Breeding Laboratories
(Raleigh, NC). The animals were fed standard chow and
distilled water ad libitum and maintained in a 12-hr light/dark
cycle. After a 10-day acclimation, mice were treated with
ENU (40 mg/kg of body weight), delivered as a single i.p.
injection of ENU diluted in dimethyl sulfoxide (9.0 mg/ml).
After injection, the mice were maintained as described above
for 6 weeks.
Mutant Isolation. Animals were killed by CO2 asphyxiation
followed by cervical dislocation and their spleens were
removed aseptically. Spleens were crushed individually with
the end of a 10-ml syringe plunger in 1 ml of RPMI-1640
medium plus Hepes buffer and 0.3% bovine serum albumin,
drawn through a 5/8-inch 25-gauge syringe needle, and ex-
pelled gently into an additional 5 ml of RPMI-1640. The cell
suspension from each spleen was then layered onto 5 ml of
Lympholyte M and spun at room temperature for 20 min at
500 x g. Mononuclear cells at the interface were removed
with a pipet and washed twice with 5 ml of the medium
described above. Cells were then resuspended in RPMI-1640
supplemented with 10%o (vol/vol) fetal bovine serum, 20%
(vol/vol) HL-1 medium, 2mM glutamine, MEM nonessential
amino acids, 20 mM Hepes buffer, 1 mM pyruvate, lx
penicillin/streptomycin, 50 tLM 2-mercaptoethanol, 4 tug of
concanavalin A per ml, and 10% (vol/vol) lymphokine-
activated killer T-cell treatment supernatant containing hu-
man interleukin 2 (a gift from Timothy Darrow, Duke Uni-
versity). Cells were enumerated with a Coulter Counter,
adjusted to a concentration of 2 x 106 cells per ml, and then
incubated for 24 hr at 37°C in a 6% CO2 humidified incubator.
A total of4 x 107 mononuclear cells per spleen were routinely
obtained. To determine plating efficiency (PE), a sample of
the culture was diluted with complete medium to 80 cells per
ml and plated in 0.1-ml aliquots in 96-well microtiter dishes
in the presence of 4 x 104 lethally irradiated (10 krads; 1 rad
= 0.01 Gy) mouse T cells per well. To isolate mutants, the
original culture was diluted to a concentration of4 x 105 cells
per ml, supplemented with 6-thioguanine (6TG, 1 ,ug/ml), and
seeded in 96-well plates at 0.1 ml per well. Plates were scored
for colony growth at x 100 magnification on day 10. The
number of clone-forming units (cfu) per well on the PE and
6TG plates was calculated by observing the fraction of
negative wells and then applying Poisson statistics. The
mutant fraction was calculated as follows: [(cfu per well on
6TG plates)(2 x 10-4)]/(cfu per well on PE plates).
Cells from positive wells were pipetted into Eppendorf
tubes and washed with Dulbecco's phosphate-buffered saline
(without magnesium). To isolate genomic DNA, cell pellets
were resuspended in 20 ,ud of digestion mix [0.5% (vol/vol)
Tween 20 and 0.1 mg ofproteinase K per ml in lx PCR buffer
(see below)], incubated at 55°C for 1 hr, boiled for 10 min, and
then frozen until needed.
PCR Conditions. To facilitate processing, aliquots ofDNA
samples were pooled in groups of two. Unless specified
otherwise, all PCR volumes were 25 ,ul and were overlaid
with 30 ,ul of mineral oil. The PCR mixtures contained lx
PCR buffer (15 mM Tris HCl, pH 8.7/2.75 mM MgCl2/60 mM
KCl), each dNTP at 0.75 mM, each primer at 1 ,uM, and 1.0
unit of Taq polymerase. The thermal cycle consisted of 1 min
at 94°C, a quick ramp to 45°C, 1 min at 45°C, a 2-min ramp
to 72°C, and 30 sec at 72°C. Initial PCR amplification from
genomic DNA used 2 ,ul of DNA solution and primers
homologous to intron sequences immediately adjacent to
exon 3 (5' primer, 5'-CCTGATTTTATTTCTATAG-3'; 3'
primer, 5'-TTTAATTATAAGTAATTATACTTAC-3').
Thirty-five cycles were performed. To analyze the high-
temperature melting domain of exon 3, the DNA from the
initial PCR was gel-purified and then used as template for a
second PCR amplification containing a GC-clamped primer
(5'-CCGCGGGCGGGCCTCGCGCCGCGGGCCGGGAC-
CCGCGGCCTGATTTTATTTCTATAG-3') and a primer
homologous to internal sequences of exon 3 (P3HI primer,
5'-TCCAGCAGGTCAGCAAA-3'). The melting characteris-
tics ofthe full-length exon 3 fragment and ofthe GC-clamped,
truncated fragment were determined by the melting algorithm
of Lerman and found to be very similar to those reported for
the human HPRT gene (13).
DGGE and Mutant Sequence Purification. Oil was removed
from PCR mixture and the volumes were adjusted to 50 ul
with water. Samples were extracted twice with phenol and
twice with chloroform. Mutant/wild-type heteroduplexes of
full-length exon 3 fragments were formed by heating samples
at 980C for 10 min and then holding at 370C for >1 hr to allow
reannealing. Mutant/wild-type heteroduplexes of GC-
clamped, truncated exon 3 fragments were formed by dena-
turing the DNA at 980C and holding overnight at 65TC.
Samples were then vacuum-dried and resuspended in 10-20
.ld of loading buffer.
One-millimeter-thick, 12.5% polyacrylamide gels (37.5:1
acrylamide/N,N'-methylenebisacrylamide weight ratio) con-
taining linear gradients of denaturant were used. An 18-36%
denaturant gradient was used to resolve mutations in the
low-temperature domain and a 36-53% gradient for the
high-temperature domain [100%o is defined as 7 M urea plus
40% (vol/vol) formamide]. Samples were loaded onto gels
submerged in a water bath at 600C and run for 15 hr at 150 V
in Tris/acetate/EDTA buffer. Gels were stained with ethid-
ium bromide and visualized under UV light. Thin slices ofgel
containing mutant/wild-type heteroduplex bands were care-
fully excised from the gel and crushed, and DNA was eluted
overnight at 40C in 100 ILI 10 mM Tris HCI, pH 8.0/1 mM
EDTA. Because the heteroduplexes isolated at this point
were usually faint and contaminated with wild-type homo-
duplex DNA, an additional round of purification was per-
formed. The supernatant from the crushed gel was diluted
25-fold into another PCR mixture and reamplified with 20
additional cycles. Samples were then processed as described
above to form heteroduplexes and loaded onto another
denaturing-gradient gel. Mutant/wild-type heteroduplexes
were again excised from the gel and eluted as above.
The supernatant containing each heteroduplex was then
diluted 25-fold into two PCR mixtures, one containing only
the upstream primer and the other containing only the
downstream primer; 15 cycles were performed. This reaction
biased the concentration of one strand of the heteroduplex
relative to the other strand. The appropriate second primer
was then added and an additional 15 cycles were performed.
To determine which PCRs produced the mutant homoduplex,
samples from each were then mixed with an equimolar
amount of known wild-type PCR product, processed to form
mutant/wild-type heteroduplexes, and run in another dena-
turing-gradient gel. The appearance of pronounced mutant/
wild-type heteroduplex bands indicated the presence of mu-
tant homoduplex in the corresponding PCR mixture. PCR
samples with mutant homoduplex DNA were diluted 50-fold
into another PCR mixture (50 ,l) containing the appropriate
downstream primer (3' primer or P3HI) and an upstream
primer (5'+C primer) that contained a universal sequencing
primer sequence attached to the 5' end of the 5' primer
sequence (5' +C primer, 5'-CAGGAAGACATTCTTTC-
CAGTTCCTGATTTTATTTCTATAG-3'). After 10 cycles,
the products were ethanol-precipitated and run in an 8%
polyacrylamide preparative gel. Bands were visualized with
ethidium bromide and UV light, excised from the gel, elec-
troeluted, and ethanol-precipitated.
DNA Sequencing. Single-stranded sequencing template was
generated by adding halfofthe electroeluted material to a 50-,l
PCR mixture with 0.5 ug of the appropriate downstream
primer and processed for 25 cycles (949C, 1 min; 440C, 15 sec;
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720C, 30 sec). The reaction mixture was extracted twice with
phenol and twice with chloroform, ethanol-precipitated,
washed, and dried. DNA was sequenced with the Sequenase/
dideoxy protocol specified by Applied Biosystems for use with
their DNA sequencer and a fluorescently tagged primer (5'-
CAGGAAGACATTCTTTCCAGTT-3').
Reconstruction Experiment. To test the quantitative nature
ofthe mutant selection system, an experiment was performed
to confirm that the PE of Hprt- cells in the presence of 6TG
and 4 x 104 wild-type cells was the same as that of cells
seeded in PE plates with irradiated feeder cells. T cells were
isolated from an E14TG2a-derived, Hprt- transgenic mouse
[(C57BL/6JLac x CBA/CaLac)F2, generously provided by
the laboratory of 0. Smithies, University of North Carolina
at Chapel Hill], primed in culture as described above, and
then seeded at different concentrations onto standard PE
plates with irradiated feeders and onto 6TG selection plates
containing the standard number of wild-type (control)
B6C3F1 cells. The number of colonies appearing on the two
types of plates was determined after incubation for 10 days.
RESULTS
The dose of ENU used in this experiment caused no overt
toxicity to animals and the PE of isolated T cells from treated
animals was indistinguishable from control values 6 weeks
after treatment (0.5-2%). The Hprt- mutant fraction in
control animals was =2 x 10-6; this is similar to the values
reported previously for the BALB/c (1) and C57BL/6 (2, 3)
mouse strains. Mutant frequency in treated animals was
=35-fold higher (7.3 x 10-5), similar to previously reported
values obtained with ENU (2). Reconstruction experiments
showed that the PE of mutants on plates containing 6TG was
indistinguishable from the PE on the PE plates (data not
shown), thus demonstrating that the observed mutation fre-
quencies measured in our experiments are good approxima-
tions of true mutation frequency existing in the T-cell pop-
ulations.
A total of 521 Hprt- mutants from 24 ENU-treated animals
were analyzed by DGGE. All mutants were first analyzed
with the full-length, unclamped exon 3 fragment (bases
135-318) to investigate the low-temperature melting domain
(bases 214-318). Mutants from single animals were also
analyzed with the GC-clamped, 5' end of exon 3 (high-
temperature melting domain; bases 135-213). Several of the
mutants detected in full-length, unclamped molecules were
ultimately shown to reside in the high-temperature melting
domain of exon 3. The heteroduplexes formed with these
mutants must have been sufficiently unstable relative to the
wild-type homoduplex to permit resolution. These mutants
also produced detectable heteroduplexes in the GC-clamped,
truncated molecules; a few of these molecules were se-
quenced to confirm the mutation observed in the full-length
molecule. Sixty-nine mutants were determined to reside in
exon 3 of Hprt (13%). The fraction of ENU-induced mutants
in exon 3 is consistent with that observed previously for the
HPRT gene in human cells treated with ENU in vitro (20).
Mutations at A-T base pairs dominated the ENU spectrum
in terms of both total mutants and number of sites mutated
(Table 1). Both transition and transversion mutations were
observed at APT base pairs. Five A-T base pairs (146, 194,
216, 220, and 233) were observed to undergo more than one
type of mutation. Mutations at G-C base pairs were observed
at two sites. One site (base 151) underwent G-C - APT
transitions and was observed multiple times in several ani-
mals. The other mutation at a G-C base pair (base 190) was
observed in one animal and was part of a double mutation that
also involved a mutation at an ArT base pair (base 216). Since
mutations at base 216 were seen separately in other animals,
the possibility exists that the mutation at base 190 may have
been an untargeted event.
In initial experiments, the T cells from several animals
were pooled prior to plating (group P1). In this group,
multiple isolates of an A-T - COG transversion at base 233
were observed. This same mutation was not observed in any
animal analyzed individually.
DISCUSSION
ENU has been shown to react with oxygens in DNA as well
as with the ring nitrogens ofguanine and adenine residues (15,
16, 21). Although many different ethylation products are
produced, modification at the 06 position ofguanine and at the
04 and 02 positions of thymine have been shown to direct
misincorporation by polymerase during DNA synthesis. 06-
Ethylguanine has been shown to induce G-C -- A-T transition
mutations (17), 04-ethylthymine has been shown to induce
AFT -+ G-C transitions (18), and 02-ethylthymine has been
shown to induce transversions (19). The mutations observed in
vivo in ENU-treated B6C3F1 mice are consistent with the
persistence and mispairing potential of these promutagenic
adducts.
Mutations at AFT base pairs accounted for 94% of all
observed mutations (Table 2). It is possible that these muta-
tions originated from spontaneous or glycosylase-mediated
depurination of 7-ethyl- or 3-ethyladenine, with subsequent
bypass replication ofapurinic sites. This possibility is unlikely,
however, given the production of similar levels of 7-ethyl- and
3-ethylguanine by ENU (21) and the lack of transversion
mutations at G-C base pairs. Therefore, given the present data,
we conclude that the transversions at AFT base pairs most
likely result from miscoding directed by 02-ethylthymine.
The paucity of mutations found at G-C base pairs relative to
those found at AFT is probably due to the efficient repair of
06-ethylguanine (22). In contrast, 04- and 02-ethylthymine
adducts have been shown to be very persistent both in vitro in
human cells (23) and in vivo in rats (24, 25). The persistence of
thymine adducts would increase the probability ofmutation at
AFT base pairs relative to G C. Furthermore, the rarity of
mutations at G-C base pairs is probably not the result of
selection bias, since a compilation ofthe literature reveals that
28 G-C and 28 AFT base pairs in exon 3 of the closely related
human HPRT gene have been observed to mutate and result
in the 6TG-resistant phenotype (26).
Thirteen of 14 thymine bases undergoing mutation (61 of62
mutations at A-T base pairs) were located on the nontran-
scribed strand of exon 3. Such strand bias has been seen
previously in in vitro mutagenesis studies with certain agents
and has been attributed to strand-specific repair of the
transcribed versus the nontranscribed strand (27, 28). If
preferential repair of the transcribed strand in vivo is the
reason for the observed strand bias with ENU, then one
would assume that thymine modification and not adenine
modification was responsible for the A-T mutations ob-
served. Another explanation for the strand bias could be
differential fidelity of leading and lagging strand replication of
ENU-adducted DNA.
One mutation (base 233, A-T - C-G) was seen multiple
times in a sample of pooled T cells from several animals but
not in any animal analyzed individually. We interpret this
phenomenon as the result of an in vivo clonal amplification of
a mutant in one animal. If base 233 were a genuine mutagenic
hotspot, it would have been detected in the animals analyzed
individually. This emphasizes the importance of analyzing
mutants separately from several animals while constructing
spectra, to rule out biases due to clonal expansion. Such
clonal expansion of HPRT- T cells in vivo has been docu-
mented previously in humans (29).
The mutational spectrum of ENU has been reported in a
variety of systems. In E. coli, transition mutations atbothGC
and A-T base pairs dominated the spectra observed in both the
gpt and lacIgenes (30, 31), in contrast to the spectra presented
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Table 1. Base-pair substitution induced in vivo in ENU-treated mice in exon 3 of Hprt
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Base 135 is defined at the first base in exon 3. The number of isolates observed at each base position is given. Five hundred twenty-one Hprr
mutations from 15 individual mice (M1-M16) and a group of 9 mice (P1) were screened for exon 3 mutations. Each of the mutations observed
would produce a change in an amino acid residue ofHPRT protein. Four mutants from mouse M15 gave ambiguous sequencing results and are
not included.
here. These data suggest that in E. coli, 06-ethylguanine and
04-ethylthymine are the most important lesions for mutagen-
esis. This difference implies that extrapolation of mutational
specificity data from E. coli to mammalian systems may not
always be a straightforward exercise. However, Eckert et al.
(32) observed that an ENU-treated plasmid inserted into an
SOS-induced E. coli gave rise to a large fraction of transver-
sions at A-T base pairs (46%). The authors suggested that
error-prone bypass of DNA-blocking lesions such as 3-ethyl-
Table 2. Types of base substitution mutations induced by ENU
in B6C3F1 mice
Mutation No.
G-C a A-T 2 (4%)
G-C - T-A 1 (2%)
G-C C-G 0 (0%70)
A-T G-C 14 (27%)
A-T C-G 6 (12%)
A-T - T-A 28 (55%)
Data are taken only from mice analyzed individually (no pooled
samples).
adenine, 02-ethylthymine, or apurinic sites could have given
rise to the transversion mutations. This spectrum is very
similar to the one observed in B6C3F1 mice.
The spectra of ENU in normal and repair-deficient human
lymphoblastoid cell lines in culture have been constructed
previously by our group (20). Comparison of mutations ob-
served in exon 3 reveals a striking similarity in the sites
mutated by ENU in culture and in vivo and in the types of
mutations induced. Five of the 16 sites seen in the present
study were also recovered in vitro in normal cells after ENU
treatment. It should be noted that the spectra obtained in vitro
were constructed by using the entire cDNA sequence and
were not "saturated" for mutations in exon 3 as in the present
study; therefore, one would anticipate that even more overlap
actually exists between the two systems. Also, the in vitro
spectra contained a large fraction of transversion mutations at
A-T base pairs, similar to that observed in the present study.
Thus, with ENU good concordance was observed between
results obtained in vitro and in vivo in cells oflymphoid origin.
The mutational spectrum of ENU has also been studied in
a nontranscribed bacterial gene inserted into a transgenic
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system appears to be qualitatively different from the results
reported here for a native gene. Six of 9 mutations (67%O)
observed were at G-C base pairs (3 GC + T-A and 3 GC -+
A*T), compared with 7 of 69 (10%) observed in the present
study (6 GEC - A*T and 1 G-C -- T*A). Only 3 of 9 mutations
(33%) were at ANT base pairs in the transgenic mice. However,
these preliminary data from transgenic mice are not sufficient
to draw strong conclusions concerning similarities or differ-
ences between the two in vivo mutagenesis systems.
The most prevalent type of mutation observed in this
study, AFT -- TEA transversions, has been previously asso-
ciated with exposure of rats and mice to ENU. In rats,
activation of the neu oncogene by a AFT -- TEA transversion
has been demonstrated in ENU-induced tumors of the pe-
ripheral nervous system (33). Also, a mutation in the 3-globin
gene ofan ENU-exposed mouse has been attributed to an AFT
-- TEA transversion by extrapolation from the amino acid
substitution in the altered gene product (34). It is interesting
that the thymine base undergoing mutation in both of these
studies is located in the nontranscribed strand.
Due to the long phenotypic expression time associated with
the 6TG-resistant phenotype (35) and the marked toxicity of
6TG to wild-type cells, the mouse T-cell cloning assay as
performed here probably selects only mutants that have been
fixed and expressed in vivo. Nevertheless, at the present time
we cannot exclude the possibility that some of the mutations
observed could have resulted from in vitro replication of
DNA containing extremely persistent DNA adducts. How-
ever, this seems unlikely given the stable mutation frequency
observed in mice up to a year after ENU exposure (2). If
replication ofpromutagenic lesions in vitro were contributing
a substantial fraction to the total number of observed muta-
tions, then one would anticipate that the mutation frequency
would decrease with time as adducts were slowly repaired.
The majority ofHprr mouse T-cell clones isolated with the
present plating technique have a limited growth potential in
vitro. Positive wells on 6TG plates rarely contain a number of
mutant cells that approaches the number of wild-type cells
originally seeded into them. The limited growth potential of
mouse T cells was a serious technical impediment to the
analysis of Hprtr mutations. However, DGGE provided a
means of purifying mutant sequences from contaminating
wild-type sequences, thus permitting unambiguous sequence
determination. The limited growth of mouse Hprtr T-cell
clones is unlike that of human T cells, which are capable of
undergoing several generations in culture after isolation. The
extended growth potential of human T cells permits the
establishment of viable mutant clonal populations that are
amenable to molecular analysis of the HPRT gene by a
cDNA/PCR approach (36).
The B6C3F1 mouse T-cell cloning/sequencing assay for
Hprt described here may represent a useful system for study-
ing the molecular mechanism of chemically induced mutation
occurring in vivo at an endogenous gene. It will be essential to
compare results from this assay with other systems to uncover
similarities and differences with other marker genes in other
species, both those which exist naturally in the animal and
those introduced in transgenic animals. It should be noted that
the analysis scheme presented here should be amenable for
use with any tissue cell type capable ofeven limited growth in
vitro. For those tissues which cannot be grown in culture, the
spectrum for a given compound can first be "saturated" in
splenic T cells to reveal the important mutagenic events in the
HPRT gene. These mutations can then be specifically detected
and quantitated in other tissues by nonselective approaches
analogous to those described by Cerutti et aL (37) and/or
Kumar et al (38).
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